Genomics
PrivateA wounded-incumbent trade dressed as a science trade — the whole SGT-003 bull case is now "clean liver" (zero DILI at N=41 vs ELEVIDYS's ~40%), but at ~$1.07B it is priced ABOVE REGENXBIO, which is 12–18 months ahead with a pivotal-endpoint hit and a Q3-2026 BLA; own the differentiation, respect that the market already paid for it.
Research
The verdict
A wounded-incumbent trade dressed as a science trade — the whole SGT-003 bull case is now "clean liver" (zero DILI at N=41 vs ELEVIDYS's ~40%), but at ~$1.07B it is priced ABOVE REGENXBIO, which is 12–18 months ahead with a pivotal-endpoint hit and a Q3-2026 BLA; own the differentiation, respect that the market already paid for it.
Primary sources
Source documents — open to read in full
Solid Biosciences is a Charlestown, Massachusetts AAV (adeno-associated virus) gene-therapy company built around one anchor asset and a fan-out of rare neuromuscular and cardiac programs. It was "purpose-built to advance the best science… for all patients with Duchenne," and was founded by families directly affected by the disease. It trades on Nasdaq Global Select as SLDB; it is a non-accelerated, smaller reporting company.
The business model in plain terms. SLDB does not sell anything and will not for years, if ever. It converts equity capital into clinical data. Each program delivers a "transgene" (a functional copy of a broken gene) packaged in an AAV capsid and driven by a tissue-specific promoter, given as a one-time IV (or, for one program, neurosurgical + IV) infusion. The bet across the whole portfolio is the same: a single dose durably restores a missing protein and changes the course of a fatal genetic disease. The asset table is the company — see Lens 5.
Products / candidates:
Customers. None today (no commercial product). Future customers would be DMD/FA/CPVT treatment centers and payers; the addressable populations are small-but-catastrophic: DMD ~10,000–15,000 US prevalence with ≥400 annual births; FA ~5,000–7,000 US / ~25,000 EU; CPVT ~33,000 US; TNNT2 DCM ~14,000–41,000 US. customers.csv is empty — correct for pre-commercial.
Suppliers. Contract development & manufacturing organizations (CDMOs) manufacture all clinical drug product at a single cGMP facility today; SLDB says it intends to establish multi-source commercial supply. This is a genuine single-point dependency (see Lens 2). CROs run the trials.
Contract structure / key terms. No revenue contracts. On the cost side, the economically important obligations are contingent milestone/royalty licenses: the FA212 asset-purchase (source of SGT-212) carries development-milestone payments SLDB may settle in cash or stock — booked as a derivative liability and remeasured quarterly ($3.35M at 3/31/26, down from $9.2M at 12/31/25). Additional licenses with the University of Florida Research Foundation (UFRF, the microdystrophin IP), the Maugeri license (Italy), and a Mayo Foundation collaboration (Dec 2024; Mayo runs preclinical→IND for six undisclosed cardiac programs, SLDB supplies viral material and picks which to clinicalize) round out the estate.
Gene therapy's supply chain is short but brittle. Map:
Upstream inputs → SLDB → patient:
Single-source dependencies: (a) one CDMO for GMP supply; (b) UFRF for the core microdystrophin IP (loss/breach would be existential for SGT-003); (c) the neurosurgical device vendor for SGT-212. Names or it didn't happen — those are the names. supply-chain.md in the commercial layer is missing for the genomics topic, so this lens is filing-grounded, not KB-derived.
For a pre-approval biotech the "moat" is really differentiation that survives contact with the clinic plus IP runway. SLDB's moats, ranked by durability:
Bargaining power. Essentially none today. As a pre-revenue buyer of scarce CDMO capacity, SLDB needs its suppliers more than they need it. Over patients it will have pricing power only if it reaches approval in a market with no disease-modifying alternative (true for CPVT and TNNT2 DCM; contested for DMD given ELEVIDYS + RGX-202). positioning.md/bottlenecks.md missing for genomics — moat read is filing- and web-grounded.
No revenue → no reportable revenue segments. The economically meaningful "segment" breakdown is R&D spend by program, which shows where management is actually betting:
| Program (allocated R&D, $000) | FY2025 | FY2024 | YoY |
|---|---|---|---|
| SGT-003 (DMD) | 58,959 | 15,197 | +288% |
| SGT-501 (CPVT) | 9,641 | 17,223 | −44% |
| SGT-212 (FA) | 5,468 | 5,874 | −7% |
| SGT-601 (TNNT2 DCM) | 7,819 | 2,773 | +182% |
| Other development programs | 5,027 | 11,055 | −55% |
| Total allocated | 86,914 | 52,122 | +67% |
| Unallocated (personnel + external) | 53,411 | 44,309 | +21% |
| Total R&D | 140,325 | 96,431 | +45.5% |
Read: this is a company that made a decision in 2025 — SGT-003 is the priority, everything else is optionality. DMD spend quadrupled (Phase 1/2 expansion + Phase 3 start + PPQ manufacturing); CPVT spend fell as it moved from tox to a cheaper early-clinical phase; FA held flat. Geographically the clinical footprint is deliberately ex-US-weighted (Australia/Canada/EU/UK for the Phase 3) — a tell about both faster enrollment and, plausibly, hedging US regulatory/political risk around gene therapy.
The asset table is the company. Every program as a row:
| Program | Indication | Modality / construct | Phase | Next value-inflection catalyst | PoS (analyst framing) |
|---|---|---|---|---|---|
| SGT-003 | Duchenne MD | POLARIS-101 (AAV-SLB101) + nNOS-microdystrophin, CK8 promoter, 1E14 vg/kg IV | Ph 1/2 INSPIRE DUCHENNE (41 dosed as of 3/18/26) → Ph 3 IMPACT DUCHENNE dosing since Apr 2026 | Mid-2026 FDA update on accelerated-approval pathway; further INSPIRE functional data; Ph3 enrollment | Lead value driver; de-risked on expression + safety, not yet on function |
| SGT-212 | Friedreich's ataxia | AAVhu68 + full-length FXN, dual IDN + IV | Ph 1b FALCON (first dosed Jan 2026, ~10 pts) | Initial data 2H-2026 | Early; novel dual-route is the differentiator and the risk |
| SGT-501 | CPVT | AAV8 + CASQ2 augmentation | Ph 1b ARTEMIS (first dosing Q2-2026) | Initial safety data 2H-2026 | Early; first-mover in a no-approved-therapy indication |
| SGT-601 | TNNT2 DCM | AAV + TNNT2 transgene, cardiac promoter | Preclinical | IND-enabling | Optionality |
| SGT-401 / SGT-701 | BAG3 / RBM20 DCM | AAV | Early preclinical / discovery | — | Optionality |
The SGT-003 interim data that matters (INSPIRE DUCHENNE, Feb 23 2026 data cut, announced Mar 11 2026):
Caveat on the "110%" headline. Public commentary cites a ~110% mean microdystrophin in the first three participants; the mature, larger Day-90 (n=20) western-blot figure is 60%. Use the filing number; the tiny-N early cut over-reads.
Management's public narrative through 1H-2026 is consistent and increasingly confident, and it has tightened around one word: liver. The messaging arc: (i) Feb 2026 — positive Type C meeting, FDA alignment on the Phase 3 design; (ii) Mar 2026 — "positive new interim data," expression durable to Day 360; (iii) Apr–May 2026 — first Phase 3 patient dosed, and the proactively stated safety line "no drug-induced liver injury, myocarditis, TMA or aHUS" as of May 4. That last phrase is not accidental — it is a direct, repeated contrast against ELEVIDYS's failure mode.
What they've started saying: "accelerated approval pathway," "commercial-readiness CMC," "PPQ batches" — the vocabulary of a company preparing to be a commercial entity. What to watch for them to stop saying: any softening of the mid-2026 accelerated-approval-update commitment. transcripts/ is empty (0 quarters on disk) — this lens is web-grounded and should be upgraded when a transcript is ingested.
Near-term catalyst calendar (the real "comps" for a clinical name are events, not multiples):
Valuation comps (market cap, all ``, as of 2026-07-02 unless noted; multiples are n/a — pre-revenue, no meaningful EV/Sales or P/E):
| Company | Ticker | Market cap | DMD gene-therapy status |
|---|---|---|---|
| Solid Biosciences | SLDB | ~$1.07B (px $10.84) | SGT-003 Ph1/2→Ph3; clean liver profile |
| REGENXBIO | RGNX | ~$687M | RGX-202 pivotal endpoint met (93%); BLA Q3-2026; ~3% severe liver injury |
| Sarepta | SRPT | ~$2.22B (5/19/26) | ELEVIDYS approved but Boxed Warning, ambulatory-only, Q1-26 sales $102M vs $375M |
| Dyne Therapeutics | DYN | ~$3.81B | DMD/DM1 exon-skipping (not gene therapy) — market's current DMD favorite |
The comp that should stop you cold: SLDB (~$1.07B) is now valued above REGENXBIO (~$687M) even though RGX-202 has a pivotal-endpoint hit, a Q3-2026 BLA, and a documented ~3% severe-liver-injury rate vs ELEVIDYS's ~40%. On any like-for-like clinical-maturity basis, RGX-202 is 12–18 months ahead of SGT-003. Either the market is paying a large premium for SGT-003's capsid/nNOS differentiation and multi-asset optionality, or SLDB has run ahead of its fundamentals. This is the central valuation tension of the whole dossier.
Mechanism comparables (by target, not by multiple): for DMD microdystrophin — ELEVIDYS (Sarepta/Roche, AAVrh74, approved, wounded) and RGX-202 (REGENXBIO, AAV8 + CT-domain microdystrophin). For FA — no gene therapy approved; SKYCLARYS (Biogen, omaveloxolone) is a small-molecule that does not address FXN deficiency. For CPVT — no approved medicine; SGT-501 would be first-in-class if it works.
SLDB is a binary-event stock: it moves on clinical data prints, FDA interactions, and — increasingly — class-wide gene-therapy safety news, not on financials. The tape confirms it: market cap roughly doubled from ~$696M (Jun 16) to ~$1.07B (Jul 2) in about two weeks, a move with no earnings event behind it — consistent with a positive read-through as the DMD-gene-therapy narrative shifted from "the class is dangerous" toward "the liver-safer assets win," plus SLDB's own Phase 3 start and mid-2026 accelerated-approval anticipation. Historically the name has been whipsawed by (i) its own trial data, (ii) the fate of the first-gen SGD-001/IGNITE DMD program (discontinued years ago), and (iii) capital raises (each large placement reset the float — see Lens 9/10). The dominant driver now is exogenous: what happens to Sarepta and to RGX-202's BLA sets the class multiple SLDB trades on. Mostly ``.
CEO — Bo (Alexander) Cumbo (since Dec 2022). This is the highest-signal fact about the company's commercial future. Cumbo spent ~8 years at Sarepta Therapeutics, rising to EVP & Chief Commercial Officer — i.e. he ran the commercial machine that launched EXONDYS/VYONDYS/AMONDYS and stood up the ELEVIDYS commercial org — then was CEO of AavantiBio (2020–2022), which Solid acquired (Dec 2022), installing him as Solid's CEO. Read: a DMD-commercial operator, not a bench scientist — exactly the profile you want if the thesis is "get a differentiated DMD gene therapy to market and sell it," and a pointed one given he is now competing against his former employer's franchise. He knows the payers, the KOLs, and the FDA-DMD dynamics intimately.
insider-transactions.csv absent); Part III comp detail is incorporated by reference to the 2026 proxy, not in the 10-K on disk — flag as an open item to verify.Acting as a forensic analyst on a pre-revenue biotech, the income statement is simple (all expense) so the risk migrates to balance-sheet estimates, dilution mechanics, and going-concern:
Regulatory findings (required):
No EPS to model (losses for the foreseeable future). The two questions that actually matter for a clinical name:
(A) Does cash reach the next value-inflection catalyst? Yes for the near-term catalysts, no for the pivotal one. Pro-forma cash ~$380.7M (3/31/26) at ~$47M/qtr burn (rising as Phase 3 scales) funds the mid-2026 accelerated-approval FDA update, the 2H-2026 FALCON + ARTEMIS data, and continued INSPIRE readouts comfortably. Management guides runway "into 1H-2028". But the IMPACT DUCHENNE 18-month primary endpoint reads out ~2H-2027–2028 and Phase 3 burn will exceed the FY2025 run-rate — so expect a capital raise in 2026–2027 ahead of pivotal data.
(B) rNPV framing of the lead asset (SGT-003), every input ``, illustrative not precise:
n/a for a single number. The honest statement: the ~$1.07B market cap already capitalizes a meaningful (>1-in-3-ish) probability of SGT-003 reaching market and winning share against RGX-202 — which is a lot to assume for the trailing asset.Brier forecast (logged conceptually, not committed in this unattended sweep): the cleanest scoreable binary is "SGT-003 receives FDA accelerated-approval-pathway alignment (i.e., FDA agrees an accelerated path is open) at the mid-2026 update" — call it p ≈ 0.55 given the constructive Type C outcome but real 2025-vintage FDA caution on DMD gene therapy. Per --watchlist rules, no forecast.ts create is run in the breadth loop; log this if promoted to a thesis.
Bull case (narrative). The DMD gene-therapy class just had its defining trauma — ELEVIDYS killed patients through the liver, got a Boxed Warning, lost its non-ambulatory indication, and saw sales collapse from $375M to $102M in a single year. In that world, the winning franchise is the one that delivers microdystrophin without frying the liver — and SGT-003 is, so far, exactly that: zero DILI across 41 patients, durable expression (60%→91% western blot to Day 360), restored nNOS via a construct no rival has, and cardiac-function stabilization in a disease where the heart is the killer. Behind it sits a genuinely diversified rare-disease engine — FA (first-in-industry dual route), CPVT (no approved therapy), a Mayo six-program cardiac pipeline, and a capsid platform with 50+ licensees. It is run by the person who built DMD commercial at Sarepta. Fully funded into 1H-2028. If accelerated approval opens in mid-2026, this re-rates hard. Contrarian view the market is under-weighting: SGT-003's clean-liver data may be worth more than a "me-too, but later" discount implies, because safety — not expression — is now the gating variable the FDA and payers care about most.
Bear case (2–3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke — what happened?). Most likely: the mid-2026 FDA update was softer than "accelerated approval is open" (FDA wanted the full Phase 3), RGX-202's Q3-2026 BLA sailed and set expectations SGT-003 now has to clear from behind, an SGT-003 (or peer) serious safety event reminded everyone AAV-DMD is dangerous, and a dilutive raise landed into a weak tape. The stock round-trips the 2026 doubling.
Are multiples too high? There are no earnings multiples; the relevant check is relative clinical value, and on that basis yes, SLDB looks rich versus RGNX — the market is paying a leader's price for the follower's asset. Justifiable only if you believe capsid/liver differentiation trumps time-to-market.
Dismantling the bull case:
Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.
A rare profitable, debt-free genomic-dx compounder (FY25 16% rev growth, $126M FCF) — but the stock has doubled into a 6.5x-sales / ~30x-FCF valuation just as Natera's FDA-approved Signatera CDx occupies the exact MIBC beachhead TrueMRD is launching into. Quality business, priced for flawless MRD execution it has not yet proven. WATCHING; would buy a reimbursement/launch-driven pullback under ~$40.
A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding.